Algorithms to battle heartworm disease Algorithms to battle heartworm disease Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Solid Fundations | Bioxcellence | Boehringer Ingelheim Solid Fundations | Bioxcellence | Boehringer Ingelheim Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
founding-member-of-QUTAC founding-member-of-QUTAC Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
Bees and biodiversity Bees and biodiversity At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
EMA filing acceptance and validation for spesolimab EMA filing acceptance and validation for spesolimab The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
1885-1948: Innovative beginnings 1885-1948: Innovative beginnings The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
cat feline diabetes medication treatment fda approval cat feline diabetes medication treatment fda approval Boehringer Ingelheim receives FDA approval for SENVELGO®
Two new claims for Nexgard range in EU and Australia Two new claims for Nexgard range in EU and Australia Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
European Metacam® indication expanded to guinea pigs European Metacam® indication expanded to guinea pigs Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.
empa-reg-outcome-recurrent-events empa-reg-outcome-recurrent-events EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Siva Thotapalli Siva Thotapalli My career challenge at Boehringer Ingelheim by Siva Thotapalli. Read it now!
preventive care cat veterinarian preventive care cat veterinarian What can we all, cat owners or veterinarians, do to promote cat health? Click to find out!
Boehringer expands cancer research at Vienna site Boehringer expands cancer research at Vienna site Boehringer Ingelheim expands cancer research at its Vienna site
additional-investment-in-Lyon-Jonage additional-investment-in-Lyon-Jonage Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim appointment to Board Managing Directors Boehringer Ingelheim announces appointments to Board of Managing Directors
Boehringer unveils first global sustainability publication Boehringer unveils first global sustainability publication Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’
Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Lothar Halmer Lothar Halmer Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
Rethinking mental health care Rethinking mental health care Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Innovation in medicinal chemistry Innovation in medicinal chemistry Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases